Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 9/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526690 | 0.83 | CIT (0.59) | IKBKBROCK2JAK2JAK3KDM4E | |
| SCHEMBL4518039 | 0.82 | AAK1 (0.60) | CTSCROCK2LMNAKDM4EALDH1A1 | |
| SCHEMBL27723723 | 0.82 | AAK1 (0.60) | CTSCROCK2LMNAKDM4EALDH1A1 | |
| SCHEMBL4512018 | 0.82 | AAK1 (0.60) | CTSCROCK2LMNAKDM4EALDH1A1 | |
| SCHEMBL4528969 | 0.82 | ROCK2 (0.47) | IKBKBROCK2JAK2JAK3KDM4E | |
| SCHEMBL4534587 | 0.79 | ROCK2 (0.45) | ROCK2JAK2JAK3KDM4ECIT | |
| SCHEMBL4522585 | 0.79 | ROCK2 (0.61) | ROCK2JAK2JAK3KDM4ECIT | |
| SCHEMBL4528422 | 0.79 | CIT (0.48) | ROCK2JAK2JAK3KDM4ECIT | |
| SCHEMBL4525156 | 0.78 | ROCK2 (0.63) | ROCK2JAK2JAK3CITLARS1 | |
| SCHEMBL4527259 | 0.76 | CIT (0.62) | ROCK2KDM4EALDH1A1CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | IKBKB 489/4885CTSC 1388/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.